Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data on breast cancer described by N.J. Bundred et al
March 26th, 2009
"Purpose of review Aromatase inhibitors improve survival in breast cancer patients but adversely affect bone health. Recent findings Hormone receptor positive breast cancer is increasingly targeted with chemotherapy, ovarian suppression and the use of aromatase inhibitors," researchers in Manchester, the United Kingdom report. "Aromatase inhibitors block oestrogen production in peripheral tissues and the three third generation aromatase inhibitors (anastrozole, letrozole and exemestane) reduce circulating oestrogen levels, leading to accelerated bone loss and an increased risk of fracture. The majority of fractures occur in osteopaenic women prescribed aromatase...
Source: Women's Health Weekly (2009-03-26)
|
